Viruses News and Research RSS Feed - Viruses News and Research

New poll reveals U.S. public's perceptions of causes of health problems

New poll reveals U.S. public's perceptions of causes of health problems

A new NPR/Robert Wood Johnson Foundation/Harvard T.H. Chan School of Public Health poll finds that more than six in ten people living in the U.S. (62%) are concerned about their future health. Nearly four in ten (39%) said that they had one or more negative childhood experiences that they believe had a harmful impact on their adult health. [More]
FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers. [More]
Scientists find gorilla origins in two human AIDS virus lineages

Scientists find gorilla origins in two human AIDS virus lineages

Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to an international team of scientists from the Perelman School of Medicine at the University of Pennsylvania, the University of Montpellier, the University of Edinburgh, and others. [More]
Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube. [More]
Modified measles vaccine effective against Chikungunya virus, study finds

Modified measles vaccine effective against Chikungunya virus, study finds

A modified, conventional measles vaccine has the potential to act against the Chikungunya virus. This is the result of a study at the University Clinic for Clinical Pharmacology of the MedUni Wien (Medical University of Vienna), which has now been published in the top journal "The Lancet Infectious Diseases". [More]
New book provides in-depth, advanced understanding of Ebola and rabies viruses

New book provides in-depth, advanced understanding of Ebola and rabies viruses

Significant human and animal pathogens remain major scourges to human health. Recent devastating Ebola virus disease outbreak in West Africa underscores the importance of understanding the biology of replication and response of host cells to infection by these pathogens. [More]
New research reveals that HIV latency is controlled by the virus itself

New research reveals that HIV latency is controlled by the virus itself

New research from the Gladstone Institutes for the first time provides strong evidence that HIV latency is controlled not by infected host cells, but by the virus itself. This fundamentally changes how scientists perceive latency, presenting it as an evolutionarily advantageous phenomenon rather than a biological accident. [More]
Researchers show how human antibodies can neutralize Marburg virus

Researchers show how human antibodies can neutralize Marburg virus

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola. [More]
TSRI scientists show how to target weak spots of Marburg virus with future treatments

TSRI scientists show how to target weak spots of Marburg virus with future treatments

Marburg virus is Ebola's deadly cousin. The virus is up to 90 percent lethal—and doctors are desperate for tools to fight it. [More]
Researchers reveal how human immune system can fight against deadly Marburg virus

Researchers reveal how human immune system can fight against deadly Marburg virus

A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University and The Scripps Research Institute have identified mechanisms involved in antibody response to the deadly Marburg virus by studying the blood of a Marburg survivor. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Study reveals causes of community-acquired pneumonia in children

Study reveals causes of community-acquired pneumonia in children

With the chill of winter comes a spike in community-acquired pneumonia (CAP), which spreads more easily as people retreat indoors and come into close contact. The lung infection triggers persistent coughing, chest pain, fever, and difficulty breathing, and is particularly hard on the very young and the very old. In fact, pneumonia is the leading cause of hospitalization among U.S. children, with estimated medical costs of $1 billion annually. [More]
Study points respiratory viruses as the most common cause of childhood pneumonia

Study points respiratory viruses as the most common cause of childhood pneumonia

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine. [More]
Simple paper strip test can rapidly diagnose Ebola

Simple paper strip test can rapidly diagnose Ebola

When diagnosing a case of Ebola, time is of the essence. However, existing diagnostic tests take at least a day or two to yield results, preventing health care workers from quickly determining whether a patient needs immediate treatment and isolation. [More]

All Fast-track diagnostics kits now available in 32 and 64 reaction sizes

Fast-track diagnostics, a global leader in the design, development and manufacture of infectious disease detection kits, will be delivering even more convenience and flexibility to customers in the way its kits are packaged and sold. From 1st March 2015, all Fast-track diagnostics kits will be sold in sizes of 32 and 64 reactions. [More]
Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical. [More]
Study identifies small loop in human prion protein that resists chronic wasting disease

Study identifies small loop in human prion protein that resists chronic wasting disease

Chronic wasting disease (CWD) — an infectious disease caused by prions — affects North American elk and deer, but has not been observed in humans. Using a mouse model that expresses an altered form of the normal human prion protein, researchers at University of California, San Diego School of Medicine have determined why the human proteins aren't corrupted when exposed to the elk prions. [More]
MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases. [More]
New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

New HPV vaccine has potential to prevent 90% of conditions triggered by HPV

A new vaccine against HPV infections has the potential to prevent 90 per cent of all of the conditions triggered by the human papillomavirus. These are the findings of a randomised, controlled, international study involving a new, 9-component vaccine against HPV used on more than 14,000 young women aged between 16 and 26 years. [More]
Study: Airport screening for disease often misses infected travellers, but can be improved

Study: Airport screening for disease often misses infected travellers, but can be improved

Scientists have shown that airport screening for disease will often miss half or more of infected travellers, but can be improved by customizing to pathogens. [More]